Declan Doogan, Director at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 108,080 shares at $67.51 ($7.3M) on 2020-06-15, disclosed to the SEC on 2020-06-17.
Scheduled sale ($7.3M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.62 | 11,164 | $733K | 10.1% |
| 2 | $66.05 | 34,336 | $2.3M | 31.2% |
| 3 | $67.51 | 18,703 | $1.3M | 17.4% |
| 4 | $68.10 | 15,797 | $1.1M | 14.8% |
| 5 | $66.94 | 2,572 | $172K | 2.4% |
| 6 | $68.73 | 25,208 |
| $1.7M |
| 23.8% |
| 7 | $69.42 | 300 | $21K | 0.3% |
| Total | $67.21 avg | 108,080 | $7.3M | 100% |
| Filing → |
| BHVN | SELL | 2022-02-11 | $5.0M | — | Filing → |
| BHVN | SELL | 2021-12-01 | $5.5M | — | Filing → |
| BHVN | SELL | 2021-11-17 | $8.8M | — | Filing → |